Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg M N Behrens

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Scientific Reports|May 3, 2018
Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions - Cologne/Bonn, Munich and Hannover, 1999-2016Melanie Stecher, Antoine Chaillon, Josef Eberle, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2006
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capturePetra Schnorrer, Georg M N Behrens, Nicholas S Wilson, et al.
HIV Medicine|August 7, 2025
Morbidity and risk factors of COVID-19 in people with HIV-1 in Europe: A combined observational cohort and nested case-control studyGeorg M N Behrens, Lambert Assoumou, Stephane De Wit, et al.
Viruses|January 8, 2025
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant RecipientsPhilippa von der Schulenburg, Georg M N Behrens, Markus Hoffmann, et al.
Plos Pathogens|November 13, 2024
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralizationLu Zhang, Hsiu-Hsin Cheng, Nadine Krüger, et al.
Vaccine|November 20, 2025
Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variantsNinaad Lasrado, Annika Rössler, Isabella McConnell, et al.
Emerging Infectious Diseases|February 24, 2022
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA VaccinationAlex Dulovic, Monika Strengert, Gema Morillas Ramos, et al.
Ebiomedicine|August 14, 2021
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysisMonika Strengert, Matthias Becker, Gema Morillas Ramos, et al.
BMC Infectious Diseases|April 26, 2022
SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune studyAlexandra Dopfer-Jablonka, Sandra Steffens, Frank Müller, et al.
Cell|January 9, 2024
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiencyLu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Scientific Reports|May 3, 2018
Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions - Cologne/Bonn, Munich and Hannover, 1999-2016Melanie Stecher, Antoine Chaillon, Josef Eberle, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2006
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capturePetra Schnorrer, Georg M N Behrens, Nicholas S Wilson, et al.
HIV Medicine|August 7, 2025
Morbidity and risk factors of COVID-19 in people with HIV-1 in Europe: A combined observational cohort and nested case-control studyGeorg M N Behrens, Lambert Assoumou, Stephane De Wit, et al.
Viruses|January 8, 2025
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant RecipientsPhilippa von der Schulenburg, Georg M N Behrens, Markus Hoffmann, et al.
Plos Pathogens|November 13, 2024
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralizationLu Zhang, Hsiu-Hsin Cheng, Nadine Krüger, et al.
Vaccine|November 20, 2025
Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variantsNinaad Lasrado, Annika Rössler, Isabella McConnell, et al.
Emerging Infectious Diseases|February 24, 2022
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA VaccinationAlex Dulovic, Monika Strengert, Gema Morillas Ramos, et al.
Ebiomedicine|August 14, 2021
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysisMonika Strengert, Matthias Becker, Gema Morillas Ramos, et al.
BMC Infectious Diseases|April 26, 2022
SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune studyAlexandra Dopfer-Jablonka, Sandra Steffens, Frank Müller, et al.
Cell|January 9, 2024
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiencyLu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Pageof 12